| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In our previous reports, we demonstrated that induction and maintain of tumor-antigen specific-memory T cells in vivo needed to successful treatment of cancer immunotherapy and that TCR avidity have played an essential role in differentiation of naive T cells to memory T cells. To evaluate accurately of TCR avidity, we tried to establish the platform cell that could reflect the function of TCR-transduced T cells. TCR avidity evaluated by TCR-transduced platform cells correlated with cytokine production, cell proliferation, and cytotoxic activity of TCR-transduced T cells. These results showed that the platform cell was a novel and stable tool for the efficient and precise evaluation of the functional avidity of isolated and transduced TCRs in developing TCR-base immunotherapy.
|
